Recombinant Mouse IN35 Protein
| 货号： | GXP57254 |
|---|---|
| Swiss Prot： | Q9D8C4 |
| 种属： | Mouse |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 1–286aa |
| 标签： | Customize |
| 纯度： | >90% |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
价格：¥2580
货期：3-4周/weeks
规格：
说明书：
产品详情
| 产品名称： | Recombinant Mouse IN35 Protein |
|---|---|
| 别名： | Ifi35 Ifp35 |
| 货号： | GXP57254 |
| Swiss Prot： | Q9D8C4 |
| 种属： | Mouse |
| 表达宿主： | E. Coli / 293F |
| 表达区间： | 1–286aa |
| 标签： | Customize |
| 纯度： | >90% |
| 实际分子量： | Depends On Tags |
| 内毒素： | < 1.0 EU/μg / < 0.1 EU/μg |
| 无载体： | Yes |
| 无动物源： | Yes |
| 制剂： | Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation. |
| 描述： | Acts as a signaling pathway regulator involved in innate immune system response (PubMed:29350881). In response to interferon IFN-alpha, associates in a complex with transcriptional regulator NMI to regulate immune response; the complex formation prevents proteasome-mediated degradation of IFI35 and correlates with IFI35 dephosphorylation (By similarity). In complex with NMI, inhibits virus-triggered type I interferon/IFN-beta production (By similarity). In complex with NMI, negatively regulates nuclear factor NF-kappa-B signaling by inhibiting the nuclear translocation, activation and transcription of the NF-kappa-B subunit p65/RELA, resulting in the inhibition of endothelial cell proliferation, migration and re-endothelialization of injured arteries (PubMed:29350881). Beside its role as an intracellular signaling pathway regulator, also functions extracellularly as damage-associated molecular patterns (DAMPs) to promote inflammation when actively released by macrophage to the extracellular space during cell injury and pathogen invasion (By similarity). Macrophage-secreted IFI35 activates NF-kappa-B signaling in adjacent macrophages through Toll-like receptor 4/TLR4 activation, thereby inducing NF-kappa-B translocation from the cytoplasm into the nucleus which promotes the release of pro-inflammatory cytokines (By similarity). {ECO:0000250|UniProtKB:P80217, ECO:0000269|PubMed:29350881}. |
| 活性测试： | Not Test |
| 复溶： |
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles. 收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。 |
| 储存： |
Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week. 未开盖的干粉蛋白在 -20°C至-80°C可保存12个月； 复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。 |
